Glembatumumab vedotin (CDX-011) is a cancer therapy targeting glycoprotein NMB (GPNMB), a protein found in some aggressive cancers. It uses a fully human IgG2 monoclonal antibody (CR011) linked to MMAE, a powerful drug that disrupts cancer cell division. The protease sensitive Val-Cit (vc) linker activates MMAE inside cancer cells, delivering precise and effective treatment.
Key Features
- Targeted Therapy: Attaches to GPNMB and delivers the drug directly to cancer cells.
- Mechanism of Action: Enters the cancer cell after binding to GPNMB, releasing MMAE to stop cell division and kill the cell.
- Precision Treatment: Focuses on cancer-specific proteins to limit harm to healthy tissues.
Clinical Development
Researchers tested glembatumumab vedotin in cancers like breast cancer and melanoma with high GPNMB expression. It earned Fast Track designation for advanced breast cancer but was discontinued after failing to show better results than existing treatments.
Applications
- Breast Cancer: Evaluated for GPNMB-positive and triple-negative breast cancers.
- Melanoma: Explored for treating melanoma with GPNMB expression.
While development ended, glembatumumab vedotin shows how ADCs can improve targeted cancer treatments and inspire future research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.